Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.89 USD
+0.04 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.88 -0.01 (-0.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Allogene Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 449 | 517 | 457 | 828 | 531 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 12 | 14 | 17 | 14 |
Total Current Assets | 459 | 529 | 471 | 845 | 545 |
Net Property & Equipment | 99 | 113 | 123 | 119 | 56 |
Investments & Advances | 4 | 72 | 370 | 208 | 63 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 17 | 20 | 16 | 15 | 9 |
Total Assets | 643 | 817 | 1,039 | 1,228 | 718 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 14 | 10 | 10 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 31 | 40 | 38 | 45 | 24 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 39 | 0 |
Total Current Liabilities | 37 | 55 | 48 | 94 | 33 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 2 | 4 | 3 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 131 | 151 | 122 | 148 | 89 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,075 | 1,912 | 1,822 | 1,726 | 1,024 |
Retained Earnings | -1,562 | -1,236 | -903 | -646 | -396 |
Other Equity | -1 | -10 | -3 | 0 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 512 | 666 | 916 | 1,080 | 629 |
Total Liabilities & Shareholder's Equity | 643 | 817 | 1,039 | 1,228 | 718 |
Total Common Equity | 512 | 666 | 916 | 1,080 | 629 |
Shares Outstanding | 168.60 | 144.20 | 142.50 | 140.20 | 121.90 |
Book Value Per Share | 3.04 | 4.62 | 6.43 | 7.70 | 5.16 |
Fiscal Year End for Allogene Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 449 | 466 | 492 | 471 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 10 | 8 | 10 | 10 |
Total Current Assets | NA | 459 | 473 | 502 | 481 |
Net Property & Equipment | NA | 99 | 103 | 106 | 110 |
Investments & Advances | NA | 4 | 38 | 63 | 54 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 17 | 20 | 20 | 20 |
Total Assets | NA | 643 | 712 | 771 | 747 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 6 | 10 | 15 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 31 | 31 | 44 | 45 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 37 | 38 | 55 | 60 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 2 | 2 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 131 | 129 | 148 | 155 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 2,075 | 2,059 | 2,039 | 1,933 |
Retained Earnings | NA | -1,562 | -1,474 | -1,413 | -1,335 |
Other Equity | NA | -1 | -2 | -4 | -6 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 512 | 583 | 623 | 592 |
Total Liabilities & Shareholder's Equity | NA | 643 | 712 | 771 | 747 |
Total Common Equity | 0 | 512 | 583 | 623 | 592 |
Shares Outstanding | 169.00 | 168.60 | 167.60 | 145.80 | 145.70 |
Book Value Per Share | 0.00 | 3.04 | 3.48 | 4.27 | 4.06 |